Lineage Cell Therapeutics, Inc. ((LCTX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: The DOSED clinical study, officially titled ‘Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device,’ aims to assess the safety and utility of a new delivery device for administering LCTOPC1. This cell therapy targets spinal cord injuries (SCI) by replacing or supporting dysfunctional cells, potentially improving quality of life and functional activity for those with traumatic cervical or thoracic injuries.
Intervention/Treatment: The intervention being tested is a biological treatment known as OPC1. It involves a single injection of 10 million LCTOPC1 cells directly into the damaged spinal tissue, designed to aid in cell replacement and support.
Study Design: This Phase 1 interventional study employs a single-group model without masking, focusing primarily on treatment. Participants receive an open-label, single injection of LCTOPC1 at one time point.
Study Timeline: The study began on February 11, 2025, with the latest update submitted on June 9, 2025. These dates are crucial as they indicate the study’s progression and current recruiting status.
Market Implications: This update could influence Lineage Cell Therapeutics’ stock performance positively, as advancements in SCI treatment may boost investor confidence. The study’s progress also positions the company competitively within the regenerative medicine sector, potentially impacting industry dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.